Umbralisib
- Generic Name
- Umbralisib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C31H24F3N5O3
- CAS Number
- 1532533-67-7
- Unique Ingredient Identifier
- 38073MQB2A
- Background
Marginal zone lymphoma is a rare, slowly progressing type of non-Hodgkin lymphoma initially treated with rituximab (an anti-CD20 drug), either alone or in combination with chemotherapy. Unfortunately, many patients experience a relapse or develop resistance to these drugs. Treatment options then become limited, and alternate treatments for the lymphoma are r...
- Indication
Umbralisib does not have any approved therapeutic indications.
- Associated Conditions
- -
- Associated Therapies
- -
Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT03828448
- Locations
- 🇺🇸
TG Therapeutics Investigational Trial Site, Nashville, Tennessee, United States
Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)
- Conditions
- Interventions
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 277
- Registration Number
- NCT03801525
- Locations
- 🇺🇸
TG Therapeutics Investigational Trial Site, Seattle, Washington, United States
🇺🇸TG Therapeutics Investigational Site, Louisville, Kentucky, United States
Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
- First Posted Date
- 2018-12-17
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 6
- Registration Number
- NCT03776864
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies
- Conditions
- Interventions
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 172
- Registration Number
- NCT03671590
- Locations
- 🇵🇱
TG Therapeutics Investigational Trial Site, Wrocław, Poland
Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL
- Conditions
- Interventions
- First Posted Date
- 2017-12-20
- Last Posted Date
- 2022-08-22
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 78
- Registration Number
- NCT03379051
- Locations
- 🇺🇸
TG Therapeutics Investigational Trial Site, Cleveland, Ohio, United States
Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-12-06
- Last Posted Date
- 2023-06-23
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT03364231
- Locations
- 🇺🇸
TG Therapeutics Investigational Trial Site, New York, New York, United States
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
- Conditions
- Interventions
- Procedure: BiopsyDrug: Bendamustine HydrochlorideProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: EchocardiographyProcedure: Multigated Acquisition ScanDrug: LenalidomideDrug: CyclophosphamideBiological: ObinutuzumabDrug: Doxorubicin HydrochlorideProcedure: Positron Emission TomographyDrug: UmbralisibDrug: PrednisoneDrug: Vincristine Sulfate
- First Posted Date
- 2017-09-01
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 95
- Registration Number
- NCT03269669
- Locations
- 🇺🇸
Mercy Hospital Saint Louis, Saint Louis, Missouri, United States
🇺🇸Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri, United States
🇺🇸Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States
Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
- First Posted Date
- 2016-06-08
- Last Posted Date
- 2022-07-21
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 710
- Registration Number
- NCT02793583
- Locations
- 🇬🇧
TG Therapeutics Investigational Trial Site, Plymouth, United Kingdom
Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy
- First Posted Date
- 2016-04-18
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT02742090
- Locations
- 🇺🇸
TG Therapeutics Investigational Trial Site, Seattle, Washington, United States
A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304
- Conditions
- Interventions
- First Posted Date
- 2016-01-14
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 116
- Registration Number
- NCT02656303
- Locations
- 🇬🇧
TG Therapeutics Investigational Trial Site, Wolverhampton, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.